Compare Novo Nordisk A/S (NVO) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ProShares UltraPro Short QQQ ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while ProShares UltraPro Short QQQ ETF trades at $40.57. The key difference: Novo Nordisk A/S pays a 3.63% dividend while ProShares UltraPro Short QQQ ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| NVO | SQQQ | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $71.70 | $97.60 |
52-Week Low | $35.29 | $36.31 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
SQQQ trades at $42.68, down 0.26% on the day, with a bullish technical signal from moving averages but neutral oscillators. As a leveraged inverse ETF, it aims to deliver -3x the daily return of the Nasdaq-100, making it a tactical tool for hedging or short-term bearish bets rather than a long-term investment. Recent news highlights its role in protecting QQQ holdings but warns of severe erosion from daily resets.
The outlook for SQQQ is highly speculative, suited only for experienced traders timing tech sector declines. Key risks include volatility decay and reliance on accurate market timing, with long-term performance showing near-total loss since inception. It offers no fundamental value like earnings or dividends, serving purely as a hedging instrument.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
